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Abstract 
 
The HepaRG cell line is a well-differentiated human hepatoma cell line exhibiting high 
expression of drug detoxifying proteins, including drug transporters. Polarized status of drug 
transporters, i.e. coordinated location of transporters at the sinusoidal or canalicular cell 
membranes, which represents a key hall-mark of hepato-biliary drug transport, remains 
however very poorly documented in HepaRG cells. In the present study, HepaRG cells were 
demonstrated to exhibit notable mRNA expression of most of sinusoidal and canalicular 
hepatic drug transporter, with a global profile of transporter expression significantly 
correlated to that displayed by freshly isolated human hepatocytes. Immunofluorescence 
studies next indicated that HepaRG cells, which exhibit bile canaliculi networks, expressed 
several main hepatic drug transporters at their sinusoidal pole, especially the influx 
transporters organic anion transporting polypeptide (OATP) 1B1, OATP2B1 and organic 
cation transporter (OCT) 1 and the efflux transporter multidrug resistance-associated protein 
(MRP) 3); in the same way, the efflux transporters P-glycoprotein and MRP2 were detected at 
the  canalicular pole of HepaRG cells.  This polarized expression of drug transporters was 
associated with saturable uptake of referent substrates for the sinusoidal transporters sodium-
taurocholate cotransporting polypeptide, OATPs and OCT1 and with canalicular secretion of 
referent substrates for the efflux transporters bile salt export pump and MRP2.  This polarized 
and functional expression of various major sinusoidal and canalicular transporters in HepaRG 
cells clearly highlights the interest of using these highly-differentiated hepatoma cells as 
surrogates for human hepatocytes in drug transporter studies. 
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Introduction 
The HepaRG cell line is a recently-characterized hepatic cell line, established from a 
hepatocholangiocarcinoma of a female patient (Gripon et al., 2002). In contrast to most, if not 
all, other available hepatic cell lines, the HepaRG cell line exhibits various liver-specific 
functions and is therefore proposed as a surrogate to the use of primary human hepatocytes, 
especially for drug metabolism and toxicity studies (Guillouzo et al., 2007; Andersson et al., 
2012). Indeed, when cultured in appropriated conditions, i.e., in the presence of 2 % (vol/vol) 
dimethylsulfoxide (DMSO), HepaRG cells express high levels of hepatic drug detoxifying 
pathways, including phase 1 enzymes, such as cytochromes P-450 1A2, 2B6 and 3A4, and 
phase 2 enzymes such as such glutathione S-transferases A1/A2, A4 and M1 and UDP-
glucuronosyl transferase 1A1 (Aninat et al., 2006; Antherieu et al., 2010). Moreover, HepaRG 
cells exhibit notable expression of drug-sensing receptors such as pregnane X receptor and 
constitutive androstane receptor (Antherieu et al., 2012) and are consequently responsive to 
inducers of drug metabolism (Kanebratt and Andersson, 2008; Turpeinen et al., 2009).  
 In addition to drug metabolizing enzymes, hepatic drug transporters are present and 
functional in HepaRG cells	   (Le Vee et al., 2006; Kotani et al., 2012). This point is likely 
noteworthy, because the important role that played hepatic drug transporters in drug-drug 
interactions and pharmacokinetics, including hepatic clearance of drugs, is now well-
recognized (Giacomini et al., 2010). Expression of transporters in HepaRG cells remains 
however incompletely characterized, especially with respect to the polarized status of these 
transporters.  Polarization into two complementary poles, i.e., a blood sinusoidal/basolateral 
pole and a biliary apical/canalicular pole, corresponds to a key hell-mark of differentiated 
hepatocytes and has important functional consequences in terms of hepato-biliary secretion of 
drugs (Chandra and Brouwer, 2004). Indeed, influx hepatic transporters expressed at the 
sinusoidal/basolateral pole of hepatocytes mediate uptake of drugs from blood into liver, 
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whereas canalicular transporters are responsible for secretion of drugs or drug metabolites 
into bile (Funk, 2008; Kock and Brouwer, 2012); in addition, some efflux transporters 
expressed at the sinusoidal membrane can secrete some drugs or drug metabolites back into 
blood, for a secondary renal elimination (Zelcer et al., 2005). The present study was therefore 
designed to carefully analyze expression and cellular location of both sinusoidal and 
canalicular hepatic transporters in HepaRG cells. Our data indicate that HepaRG cells express 
most of these transporters, with an adequate cellular localization for several of them, thus 
fully supporting the growing interest for using HepaRG cells as surrogates for human 
hepatocytes.  
 
Materials and methods 
Chemicals. Taurocholate, estrone-3-sulfate (E3S) and tetra-ethylammonium (TEA) were 
purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France), whereas carboxy-2,7-
dichlorofluoresceine (CF) diacetate was provided by Invitrogen/Life Technologies (Villebon 
sur Yvette, France).. [3H(G)] taurocholic acid (sp. act. 1.19 Ci/mmol), [6, 7-3H(N)] E3S (sp. 
act. 57.3 Ci/mmol) and [1-14C] TEA (sp. act. 2.4 mCi/mmol), were from Perkin-Elmer 
(Boston, MA). All other chemicals were commercial products of the highest purity available. 
 
Cell culture. Human highly-differentiated hepatoma HepaRG cells were routinely cultured in 
Williams' E medium supplemented with 10% (vol/vol) fetal calf serum, 100 IU/ml penicillin, 
100 µg/ml streptomycin, 5 µg/ml insulin, 2 mM glutamine, and 5 x 10–5 M hydrocortisone 
hemisuccinate; additional culture for two weeks in the same medium added with 2 % (vol/vol) 
DMSO was performed in order to get a full hepatocytic differentiation of the cells (Gripon et 
al., 2002).  
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Preparation of freshly isolated human hepatocytes. Human hepatocytes were obtained from 
adult donors undergoing hepatic resection for primary and secondary tumors, via the 
Biological Resource Center (Rennes, France). Cells were prepared by perfusion of 
histologically-normal liver fragments using a collagenase solution as previously described 
(Payen et al., 2000). 
 
RNA isolation and analysis. Total RNA was isolated from cells using the TRIzol reagent 
(Invitrogen/Life Technologies). RNA (20 ng) was then subjected to reverse transcription-
quantitative polymerase chain reaction (RT-qPCR), using the fluorescent dye SYBR Green 
methodology and an ABI Prism 7300 detector (Applied Biosystem, Foster City, CA, USA), as 
previously reported (Maubon et al., 2007). Gene primers were exactly as previously described 
(Moreau et al., 2011), except multidrug and toxin extrusion protein 1 (MATE1/SLC47A1) 
sense, GCAATCGCGGTTATCAATG, MATE1 antisense, AAGCCTGGACACATCTGGG. 
Amplification curves were next analysed with ABI Prism 7000 SDS software using the 
comparative cycle threshold method. Relative quantification of the steady-state target mRNA 
levels was calculated after normalization of the total amount of cDNA tested to a 18S mRNA 
endogenous reference using the 2(−ΔCt)method. This allowed to get a relative value of 
expression for each gene comparatively to the 18S RNA amount found in the sample, 
arbitrarily set at 106 units (Moreau et al., 2011).   
 
Light and fluorescence microscopy. Light microscopy and CF fluorescence were employed to 
monitor the presence of functional canalicular networks in HepaRG cells, as previously 
described	   (Noel et al., 2013). For light microscopy studies, cells were observed using an 
Axiovert microscope (Zeiss, Le Pecq, France). For fluorescence studies, HepaRG cells were 
incubated with 3 µM CF diacetate for 10 min at 37°C; cells were then washed with ice-cold 
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phosphate-buffered saline and visualized using a Leica DM IRB microscope (Leica 
Microsystems, Wetzlar, Germany) equipped with a black/white CoolSNAP ES camera (Roper 
Scientific, Planegg/Martinsried, Germany). Pictures were processed using the Metaview 
software. 
 
Immunolocalization studies. Immunofluorescence analyses were performed as previously 
described	  (Vee et al., 2009). HepaRG cells cultured on glass coverslips were first fixed in ice-
cold methanol for 10 min. Cells were next incubated for 2 h with mouse monoclonal 
antibodies directed against organic cation transporter 1 (OCT1)/SLC22A1 (Abcam, 
Cambridge, UK), multidrug resistance gene 1 (MDR1)/ABCB1/P-glycoprotein (Alexis 
Corporation, Lausen, Switzerland), multidrug drug resistance-associated protein (MRP) 
2/ABCC2 or MRP3/ABCC3 (Millipore Bioscience Research Reagents, Temecula, CA), with 
rabbit polyclonal antibodies directed against organic anion transporting polypeptide (OATP) 
1B1/SLCO1B1 or OATP2B1/SLCO2B1 (Huber et al., 2007), or with corresponding mouse or 
rabbit isotypic Ig controls. After washing, AlexaFluor 488- or tetramethyl rhodamine 
isothiocyanate-labeled secondary antibodies (Invitrogen/Life Technologies) were added for 1 
h, and nuclei were subsequently stained with 4,6-diamidino-2-phenylindole. 
Immunofluorescence images were finally detected with a DMRXA Leica microscope (Leica 
Microsystems) and a COHU high performance CCD camera (CohuHD, Poway, CA), using 
the Metaview software.  
 
Drug transport assays. For characterizing sinusoidal influx of taurocholate (a referent 
substrate for sodium taurocholate co-transporting polypeptide (NTCP/SLC10A1)), of E3S (a 
referent substrate for OATPs) and of TEA (a referent substrate for OCT1), HepaRG cells 
were incubated  at 37°C with 43.4 nM [3H] taurocholate, 3.4 nM [3H] E3S or  40 µM [14C] 
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TEA in the absence or presence of various concentrations of corresponding unlabelled 
substrates, using a defined sodium- and calcium-containing transport assay medium (Jigorel et 
al., 2005). Incubation times were 3 min (for taurocholate and E3S) or 5 min (for TEA); 
preliminary experiments indicated that uptakes of substrates were linear over these periods 
(data not shown). After washing in phosphate-buffered saline, cells were lyzed and 
accumulation of radiolabelled substrates was determined through scintillation counting. 
Kinetic parameters (Km and Vmax) of taurocholate, E3S and TEA uptake in HepaRG cells 
were next estimated though fitting data with Prism software (GraphPad software, La Jolla, 
CA) to Michaelis-Menten plots based on the following equation:  
    v = (Vmax x [S])/(Km + |S])  
where v is the initial uptake rate of substrate, [S] is the substrate concentration in the 
medium, Km is the Michaelis–Menten constant, and Vmax is the maximum uptake rate.  
 Biliary secretion of taurocholate and CF was analyzed through determination of drug 
accumulation into bile canaliculi-like structures as previously reported (Annaert et al., 2001). 
Briefly, HepaRG cells were first incubated for 10 min at 37°C with transport assay buffer 
containing Ca2+ or with the same buffer, except that 1.8 mM CaCl2 was withdrawed and 100 
µM EGTA was added, knowing that incubation with this Ca2+-free buffer promotes disruption 
of tight junctions and opening of bile canaliculi networks. Buffers were then removed and 
HepaRG cells were further incubated for 10 min at 37°C in transport assay medium 
containing 43.4 nM [3H] taurocholate or 3 µM CF diacetate. After washing with ice-cold 
phosphate-buffered saline, accumulations of taurocholate and CF into cells + bile canaliculi 
(Ca2+-containing conditions) and into cells only (Ca2+-free conditions) were determined by 
scintillation counting (for taurocholate) or spectrofluorimetry (for CF) using a SpectraMax 
Gemini SX spectrofluorometer (Molecular Devices, Sunnyvale, CA) (excitation and emission 
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wavelengths were 485 and 535 nm, respectively). Biliary excretion index (BEI) was finally 
calculated using the following equation (Liu et al., 1999): 
 
Statistical analysis. Quantitative data were statistically analyzed using Student’s t-test paired 
or nonparametric Spearman’s rank correlation method. The criterion of significance 
was p < 0.05.   
 
Results and Discussion 
Expression of sinusoidal and canalicular drug transporters in HepaRG cells was first 
determined by RT-qPCR and compared to that found in freshly isolated human hepatocytes. 
These freshly isolated human hepatocytes were chosen as referent cells, in contrast to 
previous studies using primary hepatocytes or cryopreserved hepatocytes as references (Le 
Vee et al., 2006; Antherieu et al., 2010; Kotani et al., 2012), because placing hepatocytes in 
culture or cryopreservation are susceptible to alter drug detoxifying protein expression and 
activity, including those of transporters (Badolo et al., 2011; Ramboer et al., 2013). Moreover, 
freshly isolated human hepatocytes were obtained from 8 donors, in order to take into 
consideration potential major inter-individual differences in drug transporter mRNA levels. 
As shown in Fig 1A, expressions of sinusoidal influx solute carrier (SLC) transporters such as 
NTCP, OATPs, OCT1 and organic anion transporter 2 (OAT2/SLC22A7), were reduced in 
HepaRG cells when compared to hepatocytes. Nevertheless, when considering mRNA levels 
expressed in arbitrary units, substantial expressions (> 5 arbitrary units) of NTCP, OATP1B1, 
OATP2B1, OCT1 and OAT2 were detected in HepaRG cells, knowing that these transporters 
were otherwise highly expressed in freshly isolated human hepatocytes (Fig. 1A). Only 
Accumulation (Cells+Bile canaliculi)
BEI= 
Accumulation (Cells+Bile canaliculi) – Accumulation (Cells)
X 100
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OATP1B3, which is markedly down-regulated in HepaRG cells when compared to 
hepatocytes, was finally very poorly expressed in HepaRG cells (expression < 1 arbitrary 
unit), in agreement with a recent report (Kotani et al., 2012). In contrast to SLC transporters, 
sinusoidal ATP-binding cassette (ABC) efflux transporters, except MRP6 (ABCC6), were up-
regulated in HepaRG cells when compared to human hepatocytes (Fig. 1A); levels of 
expressions of MRP1, MRP4 and MRP5 remained however low in HepaRG cells (expression 
< 5 arbitrary units), unlike that of MRP3 (expression = 45.0 arbitrary units). With respect to 
canalicular transporters, some of them, such as MRP2 and especially MDR1, were induced in 
HepaRG cells, when compared to human hepatocytes (Fig. 1B). By contrast, the canalicular 
SLC transporter MATE1 remained unchanged, whereas breast cancer resistance protein 
(BCRP/ABCG2) and especially bile salt export pump (BSEP/ABCB11) were down-regulated 
(Fig. 1B).  
 To more globally characterize drug transporter expression in HepaRG cells and human 
hepatocytes, sinusoidal and canalicular drug transporters were next ranked from the most 
expressed to the less expressed according to mRNA level of expression and the resulting 
expression profiles were compared. As shown in Fig. 1C, expression profile of drug 
transporters in HepaRG cells was significantly correlated with that exhibited by freshly 
isolated human hepatocytes. Therefore, even if some discrepancies in mRNA levels of drug 
transporters exist between HepaRG cells and human hepatocytes, as reported above, this does 
not result in an altered profile of transporter expression in HepaRG cells when compared to 
that found in normal hepatocytes.  
 DMSO-treated differentiated HepaRG cells are well-known to be polarized (Antherieu 
et al., 2012) and consequently exhibit bile canaliculi-like structures, which are fully functional 
because they accumulated the fluorescent dye CF (Fig. 2A). Immunofluorescence studies next 
indicated that various hepatic transporters such as OATP1B1, OATP2B1, OCT1 and MRP3, 
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known to be physiologically present at the sinusoidal pole of hepatocytes in the liver (Funk, 
2008), were similarly expressed at the sinusoidal-like pole of cultured HepaRG cells (Fig. 
2B).  In the same way, the canalicular ABC transporters MDR1/P-glycoprotein and MRP2 
were located to the bile canaliculi-like structures of HepaRG cultures (Fig. 2B). Taken 
together, these data suggest that transporter expression is correctly polarized in HepaRG cells; 
this point is noteworthy, because polarized localization of transporter is crucial for in vitro 
models of hepatic drug transport, and is well-exhibited by the present gold standard of these 
models, i.e., sandwich-cultured hepatocytes (Swift et al., 2010).  
 HepaRG cells have previously been shown to exhibit sinusoidal transport activity, 
especially NTCP-mediated uptake of taurocholate, OATP-mediated uptake of E3S, estradiol-
17β glucuronide and pitavastatin, and OCT1-mediated uptake of TEA (Le Vee et al., 2006; 
Kotani et al., 2012). In order to better characterize some of these sinusoidal transport 
activities, we determined their kinetic parameters. As shown in Fig 3A, uptake of taurocholate 
in HepaRG cells was found to be saturable, with a Km value (6.3 µM) closed to that described 
for NTCP-mediated taurocholate in NTCP-transfected cells (Km=7.9 µM) (Kim et al., 1999). 
E3S uptake was also saturable in HepaRG cells (Fig. 3A), with a Km value (44.0 µM) nearly 
identical to that corresponding to the low-affinity binding site for OATP1B1-mediated E3S 
transport in OATP1B1-transfected cells (Km=45.0 µM)	  (Noe et al., 2007). A contribution of 
the high-affinity binding site of OATP1B1 for E3S (Km=0.09 µM) (Tamai et al., 2001) and of 
OATP2B1, which is well known to transport E3S (Km=10.2 µM) (Noe et al., 2007) and is 
expressed in HepaRG cells at substantial level (Fig. 1A), has however likely to be additionally 
taken into consideration for E3S influx in HepaRG cells. By contrast, a role for OATP1B3 
may be discarded, since this transporter is only present at a very low level in HepaRG cells 
(Fig. 1A). TEA uptake was also found to be saturable in HepaRG cells (Fig. 3A), with 
however a Km value (1.44 mM) higher than those reported for TEA uptake in OCT1-
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transfected cells, that ranged from 69.2 µM to 229.0 µM (Zhang et al., 1998; Umehara et al., 
2007). The reason for such a discrepancy between Km values for TEA uptake in OCT1-
expressing HepaRG cells versus OCT1-transfected cells remains to be clarified; it could be 
linked to post-transcriptional processes specifically targeting OCT1 in HepaRG cells, such as 
phosphorylation or glycosylation, or, alternatively, to the artificially elevated levels of OCT1 
in OCT1-transfected cells. 
 Canalicular secretion of taurocholate and CF was finally quantified in HepaRG cells 
using the BEI approach based on Ca2+ withdrawal-mediated disruption of canaliculi (Liu et 
al., 1999). As shown in Fig. 3B, HepaRG cells pre-incubated in Ca2+-free conditions exhibited 
decreased retention of taurocholate and CF comparatively to counterparts maintained in the 
presence of Ca2+, which indicates that HepaRG cells secreted taurocholate and CF in bile 
canaliculi-like structures and agrees, for CF, with Fig. 2A. BSEP and MRP2, that handle 
taurocholate and CF, respectively	  (Meier and Stieger, 2002; Zamek-Gliszczynski et al., 2003), 
at the canalicular pole of hepatocytes, appear therefore to be most likely functional in 
HepaRG cells. Interestingly, BEI value for CF in HepaRG cells (34.4 %) was nearly identical 
to CF BEI value reported in sandwich-cultured human hepatocytes (BEI=34%)	  (Hoffmaster et 
al., 2004), which suggests that MRP2 is similarly active in these primary human hepatocytes 
and in HepaRG cells. By contrast, taurocholate BEI values in sandwich-cultured human 
hepatocytes (around 70-75%) (Marion et al., 2007) are rather higher than that found in 
HepaRG cells (BEI=29.2%), which likely indicates a lower BSEP activity in HepaRG cells, 
consistent with the down-regulation of BSEP mRNA expression observed in these hepatoma 
cells (Fig. 1B).  
 In summary, HepaRG cells were demonstrated to exhibit a polarized and functional 
expression of various major sinusoidal and canalicular transporters, with a global drug 
transporter mRNA level profile correlated to that displayed by freshly isolated human 
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hepatocytes. Otherwise, HepaRG cells have been shown to be fully responsive to 
physiological, pharmacological or toxicological stimuli regulating hepatic transporter 
expression (Fardel and Le Vee, 2009; Lambert et al., 2009). Taken together, these data clearly 
highlight the interest of using HepaRG cells in drug transporter studies as surrogates for 
human hepatocytes, even if some quantitative differences between HepaRG cells and human 
hepatocytes with respect to transporter expression levels and transport parameters exist and 
have likely to be kept in mind.  
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Legends to figures 
Fig. 1. Sinusoidal and canalicular drug transporter mRNA expression in HepaRG cells. 
(A, B) Expression of sinusoidal (A) and canalicular (B) drug transporter expression was 
determined in HepaRG cells and freshly isolated human hepatocytes (FIHH) by RT-qPCR as 
described in Materials and Methods. Data from 8 independent HepaRG cultures and from 8 
independent hepatocyte populations are expressed as boxplots. Transporter expression in 
HepaRG cells expressed as % of that found in human hepatocytes (arbitrarily set at 100 %) 
are indicated by numbers in brackets.*, p<0.05 when compared to hepatocytes. (C) Drug 
transporters were ranked according to their level of mRNA expression; correlation between 
transporter expression profiles was next analyzed using the Spearman's rank correlation 
method. Spearman's rank coefficient (ρ) and p values are indicated at the top of the 
correlation graph. 
Fig. 2. Drug transporter localization in HepaRG cells. 
(A) HepaRG cell morphology was examined by light phase contrast microscopy whereas CF-
labeled functional bile canaliculi were detected through fluorescence microscopy; lile 
canaliculi are indicated by arrows. Bar = 30 µM. (B) Immunolocalization of sinusoidal and 
canalicular drug transporters was performed as described in Materials and Methods. Pictures 
correspond to single immunolabeling, with membrane transporter-related green fluorescence, 
except bottom right picture, for which double immunolabeling was performed (red 
fluorescence for MRP2 and green fluorescence for OATP1B1); blue fluorescence corresponds 
to 4,6-diamidino-2-phenylindole-stained nuclei. Bar = 10 µM. 
Fig. 3. Sinusoidal (A) and canalicular (B) drug transport activity in HepaRG cells. 
(A) Saturable uptakes of referent substrates for sinusoidal transporters (Taurocholate for 
NTCP, E3S for OATPs and TEA for OCT1) were analyzed as described in Materials and 
Methods. Data are the means + SEM of three independent experiments. Kinetic parameters 
21	  
	  
(Km, Vmax) are indicated on the top of each graph. (B) Canalicular secretions of the BSEP 
substrate taurocholate and the MRP2 substrate CF were determined as described in Material 
and Methods. Data are the means + SEM of five (Taurocholate) or four (CF) independent 
experiments. BEI values are indicated on the top of each graph. *, p<0.05. 
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